The store will not work correctly when cookies are disabled.
5-chloro-4-((5-chloro-6-cyclopropylpyridin-3-yl)oxy)-2-fluoro-N-(methylsulfonyl)benzamide
ID: ALA5286125
Chembl Id: CHEMBL5286125
Max Phase: Preclinical
Molecular Formula: C16H13Cl2FN2O4S
Molecular Weight: 419.26
Associated Items:
Names and Identifiers
Canonical SMILES: CS(=O)(=O)NC(=O)c1cc(Cl)c(Oc2cnc(C3CC3)c(Cl)c2)cc1F
Standard InChI: InChI=1S/C16H13Cl2FN2O4S/c1-26(23,24)21-16(22)10-5-11(17)14(6-13(10)19)25-9-4-12(18)15(20-7-9)8-2-3-8/h4-8H,2-3H2,1H3,(H,21,22)
Standard InChI Key: BJBQASWPUALPOY-UHFFFAOYSA-N
Associated Targets(Human)
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 419.26 | Molecular Weight (Monoisotopic): 417.9957 | AlogP: 3.89 | #Rotatable Bonds: 5 |
Polar Surface Area: 85.36 | Molecular Species: ACID | HBA: 5 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 4.06 | CX Basic pKa: 3.01 | CX LogP: 2.56 | CX LogD: 1.91 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.80 | Np Likeness Score: -1.19 |
References
1. Kitano Y, Shinozuka T.. (2022) Inhibition of NaV1.7: the possibility of ideal analgesics., 13 (8.0): [PMID:36092147] [10.1039/d2md00081d] |
2. Karanjule N, Hayashi N, Suzuki S, Tsuda T, Tokumaru E, Tanaka K, Kimoto H, Domon Y, Takahashi S, Kubota K, Kitano Y, Yokoyama T, Koishi R, Fujiwara C, Inaba S, Asano D, Sakakura T, Takasuna K, Shinozuka T.. (2023) N-Aryl Indoles as a Novel Class of Potent NaV1.7 Inhibitors., 14 (6): [PMID:37312847] [10.1021/acsmedchemlett.3c00079] |